autonomic nervous system disease: A disease involving the autonomic nervous system.
Other and unspecified disorders of autonomic nervous system
DOID EFO Endpoint Browser PheWeb
G6_AUTOTHUNS
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
148 |
4. Check minimum number of eventsNone |
148 |
5. Include endpointsNone |
148 |
6. Filter based on genotype QC (FinnGen only) |
145 |
Control definitions (FinnGen only)
- Control exclude
- G6_AUTONOM
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Other and unspecified disorders of autonomic nervous system
based on the number of shared cases.
Similar with more cases:
- Autonomic disorders
- Other neurological diseases
- Neurological diseases
- Neurological diseases, wide definition
- Any operation in hilmo
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1130 | 550 | 569 |
| Only index persons | 923 | 477 | 446 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.02 | 0.02 |
| Only index persons | 0.02 | 0.02 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 50.73 | 48.91 | 52.18 |
| Only index persons | 48.28 | 47.06 | 49.57 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 145 | 89 | 56 |
| Unadjusted period prevalence (%) | 0.03 | 0.03 | 0.03 |
| Median age at first event (years) | 49.01 | 47.14 | 51.99 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 148
- Matched controls
- 1480
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
G90.8
ICD-10 Finland
Other disorders of autonomic nervous system
+∞
79.5
69
*
G90.9
ICD-10 Finland
Disorder of autonomic nervous system, unspecified
+∞
73.1
64
*
U09.9
ICD-10 Finland
Post COVID-19 condition, unspecified
34.6
20.5
26
9
R53
ICD-10 Finland
Malaise and fatigue
4.2
16.5
66
236
R03DC03
ATC
montelukast; oral
4.6
15.3
47
137
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
5.3
14.2
33
76
N03AX16
ATC
[U] pregabalin
3.9
13.8
56
199
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
5.9
13.5
27
54
N06AX21
ATC
duloxetine; oral
4.4
12.1
36
101
G93.3
ICD-10 Finland
Postviral fatigue syndrome
25.4
11.8
16
7
C07AB07
ATC
bisoprolol; oral
3.3
11.5
86
439
R55
ICD-10 Finland
Syncope and collapse
4.7
10.8
28
70
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
5.4
10.7
23
49
3378X
ICD-9 Finland
Disorders of the autonomic nervous system[NEUROPATHIA AUTONOMICA PERIPHERICA ALIA DEFINITA]
+∞
10.5
10
*
R68.88
ICD-10 Finland
Other specified general symptoms and signs, not elsewhere classified.
25.5
10.5
14
6
XQ800
NOMESCO Finland
Prick test
5.1
9.7
22
49
H02AA02
ATC
fludrocortisone; oral
106.6
9.5
10
*
N05BA04
ATC
oxazepam; oral
3.0
8.8
54
239
N06AX16
ATC
venlafaxine; oral
3.4
8.7
37
131
A99
ICPC
Disease/condition unspecnature/site
4.2
8.6
25
68
N28
ICPC
Limited function/disability (N)
35.5
8.2
10
*
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
5.1
8.1
18
39
N03AX12
ATC
[U] gabapentin; oral
3.2
8.0
37
138
AA1AD
NOMESCO Finland
CT of head and brain
2.9
7.9
48
209
Z01.8
ICD-10 Finland
Other specified special examinations
2.9
7.7
46
199
Z2446
NOMESCO Finland
Social worker
4.6
7.5
19
46
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
3.5
7.4
28
92
G90.0
ICD-10 Finland
Idiopathic peripheral autonomic neuropathy
+∞
7.3
7
*
N03AE01
ATC
clonazepam; systemic
7.0
7.2
17
27
A02BC02
ATC
pantoprazole; systemic
2.7
7.1
107
722
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
3.4
7.1
29
100
K59.09
ICD-10 Finland
Constipation, unspecified
4.7
7.0
17
40
N06AX12
ATC
bupropion; oral
4.1
6.9
20
54
SPAT1220
SPAT
Assessment of need for rehabilitation and/or rehabilitation plan
6.5
6.8
17
29
U09
ICD-10 Finland
Post COVID-19 condition
23.8
6.8
9
*
A06AC01
ATC
ispaghula (psylla seeds); oral
2.7
6.6
45
206
F41.2
ICD-10 Finland
Mixed anxiety and depressive disorder
3.1
6.6
31
116
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.6
6.5
50
243
F32.9
ICD-10 Finland
Depressive episode, unspecified
3.2
6.5
29
105
A28
ICPC
Limited function/disability NOS
3.1
6.5
30
111
H05BA01
ATC
calcitonin (salmon synthetic); nasal, parenteral
15.2
6.5
10
7
G62.8
ICD-10 Finland
Other specified polyneuropathies
72.9
6.5
7
*
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
3.6
6.5
23
72
R06.0
ICD-10 Finland
Dyspnoea
2.6
6.5
52
259
C07AA05
ATC
propranolol; systemic
2.7
6.4
43
196
R42
ICD-10 Finland
Dizziness and giddiness
2.7
6.3
41
183
N99
ICPC
Neurological disease other
28.0
6.3
8
*
J01MA02
ATC
ciprofloxacin; systemic
2.4
6.3
62
339
L28
ICPC
Limited function/disability (L)
3.1
6.2
29
108
L29
ICPC
Musculoskeletal sympt/complt other
3.7
6.1
21
64
Z01.5
ICD-10 Finland
Diagnostic skin and sensitization tests
3.7
6.1
21
64
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.4
6.1
70
408
JN3AA
NOMESCO Finland
Abdominal X-ray examination without contrast
6.9
6.0
14
22
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
79
330
3.99
15.67
2.6
2.0
213.73
229.79
u/l
0.05
74
320
90
487
3.16
10.61
3.0
2.2
82.31
75.44
nmol/l
1.24
80
443
94
550
2.94
9.15
9.1
7.4
1.22
1.22
mmol/l
0.01
83
475
77
414
2.79
8.67
2.3
1.8
100.68
96.64
pmol/l
0.41
39
219
109
703
3.09
8.65
10.6
9.3
3.82
4.06
e9/l
0.68
96
621
81
450
2.77
8.51
6.3
4.8
36.29
36.48
g/l
0.13
75
431
55
261
2.76
7.71
2.5
1.8
0.54
0.94
mg/l
2.51
42
198
83
496
2.53
7.12
7.4
6.6
1.21
1.22
mmol/l
0.28
77
464
122
891
3.10
6.77
5.5
3.9
9.22
10.17
mm/h
0.49
115
826
16
40
4.36
6.07
1.5
1.5
0.20
0.23
g/l
0.86
16
40
16
40
4.36
6.07
1.4
1.5
1.03
1.15
g/l
0.69
16
40
91
595
2.37
6.05
4.3
2.6
132.45
97.31
ug/l
0.26
85
561
14
24
6.32
5.69
2.9
3.0
25.74
23.97
mmol/l
0.66
14
24
24
91
2.95
4.94
2.3
2.3
0.23
0.23
g/l
0.13
24
85
117
894
2.47
4.91
8.3
7.1
76.30
74.50
u/l
0.24
110
845
15
35
4.65
4.79
1.6
3.0
—
—
—
0
0
13
26
5.37
4.76
1.3
1.3
—
—
—
0
0
10
14
7.57
4.73
1.2
1.0
—
—
—
0
0
94
665
2.13
4.64
6.2
5.0
6.86
6.44
mmol/l
0.78
88
606
120
937
2.48
4.63
5.4
3.8
14.88
14.48
pmol/l
1.07
115
867
12
23
5.58
4.56
1.4
1.4
—
—
—
0
0
13
29
4.81
4.37
1.7
1.4
—
—
—
0
0
20
74
2.97
4.29
1.0
1.0
—
—
—
0
0
24
99
2.70
4.23
1.4
1.2
125.47
107.67
iu/ml
0.10
11
42
41
219
2.21
4.14
1.5
1.3
4.51
10.94
u/ml
0.88
17
96
62
392
2.00
4.00
4.4
3.5
15.02
40.37
ng/l
1.66
31
250
63
401
1.99
3.98
4.8
3.0
—
—
—
0
0
9
15
6.31
3.88
1.2
1.0
—
—
—
0
0
38
202
2.19
3.86
1.7
1.8
432.73
454.97
pmol/l
0.20
30
174
33
167
2.26
3.77
2.1
1.6
1172.82
1139.40
nmol/l
0.07
24
129
9
16
5.91
3.72
1.2
1.0
—
—
—
0
0
35
185
2.17
3.59
1.9
2.6
2.44
2.43
mmol/l
0.08
28
166
50
304
1.97
3.53
1.5
1.3
9.96
1.57
u/ml
0.68
18
79
69
470
1.88
3.45
11.1
13.1
1.29
1.25
inr
0.13
19
136
48
290
1.97
3.44
2.9
2.6
323.20
4201.30
umol/l
1.05
40
258
15
54
2.98
3.37
1.7
1.4
7.29
3.50
mg/l
—
10
40
24
111
2.39
3.35
2.3
2.3
41.39
28.72
u/l
0.38
18
94
83
604
1.85
3.33
4.8
5.7
12.14
12.78
umol/l
0.08
75
572
52
327
1.91
3.30
5.0
2.7
0.18
0.40
e6/l
1.06
40
245
13
44
3.14
3.22
2.8
1.5
—
—
—
0
0
131
1121
2.47
3.19
6.9
4.4
2.22
1.82
mu/l
0.33
123
1041
34
186
2.07
3.18
5.4
2.7
288.24
102.72
ng/l
0.30
21
123
28
144
2.16
3.06
2.4
2.9
9.17
5.98
umol/l
0.28
23
125
5
5
10.28
3.00
1.0
1.0
—
—
—
0
0
131
1131
2.38
2.95
15.7
11.1
90.88
87.40
ml/min/173m2
0.95
112
923
44
272
1.88
2.89
3.5
3.0
580.71
1006.42
ng/l
1.37
38
222
78
578
1.74
2.77
5.0
3.3
0.00
0.00
estimate
-0.00
21
120
5
6
8.57
2.77
1.4
1.8
—
—
—
0
0
45
284
1.84
2.76
2.8
1.8
2.82
2.90
mg/l
0.09
38
248
12
41
3.09
2.69
2.5
2.5
156.67
187.71
%
0.43
12
41
10
30
3.50
2.66
1.5
1.5
0.48
0.23
nmol/l
—
10
24
138
1233
2.76
2.63
22.0
12.2
16.32
21.46
mg/l
1.52
109
943
9
25
3.76
2.62
1.0
1.1
—
—
—
0
0
6
11
5.63
2.57
1.0
1.0
—
—
—
0
0
38
235
1.83
2.46
1.5
1.2
73.86
30.37
iu/ml
0.51
12
80
30
172
1.93
2.45
3.6
2.6
3.62
2.49
e6/l
0.22
17
85
8
22
3.78
2.40
1.3
1.0
—
—
—
0
0
21
106
2.14
2.40
8.2
11.6
1.61
1.52
mmol/l
0.06
15
84
7
17
4.27
2.39
1.6
1.4
0.37
0.42
nmol/l
—
7
17
5
8
6.42
2.39
2.0
1.1
—
—
—
0
0
5
8
6.42
2.39
2.0
1.1
—
—
—
0
0
77
587
1.65
2.33
5.0
3.3
0.00
0.00
estimate
-0.00
20
107
6
13
4.76
2.29
1.2
3.5
2.43
1.37
nmol/l
—
6
13
15
67
2.38
2.26
4.2
4.7
25.51
24.43
mmol/l
0.82
15
67
10
35
2.99
2.25
1.7
1.1
—
—
—
0
0
45
300
1.72
2.25
5.1
3.7
30.62
10.21
mg/mmol
0.48
25
183
76
583
1.62
2.21
7.6
4.5
0.00
0.00
estimate
-0.00
20
115
54
381
1.66
2.18
3.7
3.4
2.35
2.36
mmol/l
0.09
44
341
6
14
4.42
2.17
1.5
1.3
450.17
246.50
pmol/l
—
6
14
5
10
5.13
2.08
1.6
2.4
—
—
—
0
0
5
10
5.13
2.08
1.4
1.2
—
—
—
0
0
10
39
2.68
1.98
1.3
3.2
—
—
—
0
0
5
11
4.66
1.95
1.4
1.2
—
—
—
0
0
61
454
1.58
1.95
5.0
3.3
—
—
—
0
0
30
187
1.76
1.88
3.7
2.5
0.61
1.01
e6/l
0.88
17
99
5
12
4.27
1.84
1.0
2.0
—
—
—
0
0
6
19
3.25
1.68
2.5
1.5
—
—
—
0
0
27
169
1.73
1.67
1.9
1.9
—
—
—
0
0
12
56
2.24
1.66
2.1
1.8
—
—
—
0
0
5
14
3.66
1.63
4.0
1.3
—
—
—
0
0
5
15
3.41
1.53
1.0
1.9
—
—
—
0
0
5
16
3.20
1.45
1.0
2.0
—
—
—
0
0
6
22
2.80
1.45
2.0
3.2
135.17
128.23
g/l
—
6
13
14
74
1.99
1.44
1.6
1.5
—
—
—
0
0
12
61
2.05
1.37
2.4
1.9
—
—
—
0
0
138
1292
2.01
1.32
12.8
9.4
25.86
25.29
u/l
0.17
132
1252
19
116
1.73
1.29
2.3
1.7
—
—
—
0
0
117
1053
1.53
1.28
6.0
4.8
39.92
38.68
mmol/mol
0.60
110
995
19
117
1.72
1.25
2.2
1.6
—
—
—
0
0
12
65
1.92
1.17
1.5
1.3
—
—
—
0
0
5
20
2.55
1.16
1.0
1.8
—
—
—
0
0
125
1152
1.55
1.11
4.2
4.0
6.13
5.79
mmol/l
0.88
117
1070
8
41
2.00
1.10
1.4
1.1
—
—
—
0
0
5
21
2.43
1.10
1.6
1.0
—
—
—
0
0
5
21
2.43
1.10
1.6
1.0
—
—
—
0
0
35
259
1.46
1.09
1.9
2.2
—
—
—
0
0
16
98
1.71
1.08
2.4
3.1
—
—
—
0
0
9
52
1.78
0.94
4.3
2.3
0.80
1.21
%
—
9
52
40
312
1.39
0.93
4.2
3.4
0.00
0.00
estimate
-0.00
20
111
97
878
1.30
0.78
3.3
2.9
57.06
39.54
u/l
0.55
87
835
5
24
2.12
0.75
1.0
1.4
—
—
—
0
0
7
40
1.79
0.72
1.1
1.1
—
—
—
0
0
5
28
1.81
0.67
1.8
2.3
—
—
—
0
0
8
50
1.63
0.62
1.0
1.2
—
—
—
0
0
5
30
1.69
0.62
1.2
1.2
—
—
—
0
0
14
98
1.47
0.59
1.8
1.9
—
—
—
0
0
17
124
1.42
0.59
2.1
1.9
—
—
—
0
0
26
209
1.30
0.51
3.2
2.2
—
—
—
0
0
34
284
1.26
0.50
1.4
1.6
—
—
—
0
0
7
48
1.48
0.47
1.4
1.5
—
—
—
0
0
32
269
1.24
0.45
1.4
1.5
—
—
—
0
0
10
139
0.70
0.44
2.0
1.7
—
—
—
0
0
28
232
1.26
0.44
3.2
2.4
—
—
—
0
0
0
16
0.00
0.41
0.0
1.2
—
—
—
0
0
9
76
1.20
0.25
2.9
1.4
—
—
—
0
0
27
240
1.15
0.22
4.3
4.2
23.05
22.76
%
0.03
11
117
5
42
1.20
0.21
1.0
1.9
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
0
13
0.00
0.21
0.0
3.2
—
90.31
—
0
13
0
14
0.00
0.20
0.0
2.1
—
—
—
0
0
0
14
0.00
0.20
0.0
2.1
—
—
—
0
0
0
14
0.00
0.20
0.0
2.1
—
—
—
0
0
15
173
0.85
0.18
3.3
2.8
0.78
0.71
ug/l
—
8
120
140
1383
1.23
0.14
32.1
18.2
4.48
4.51
e12/l
0.33
134
1352
140
1382
1.24
0.14
32.2
18.2
40.14
40.50
%
0.35
131
1313
5
44
1.14
0.10
1.0
2.3
—
—
—
0
0
119
1208
0.92
0.10
5.3
4.3
2.89
2.78
mmol/l
0.56
111
1126
14
127
1.11
0.08
9.1
6.8
—
—
—
0
0
94
925
1.04
0.06
4.9
3.6
—
—
—
0
0
114
1151
0.96
0.04
4.5
3.5
1.41
1.24
mmol/l
1.05
107
1066
118
1190
0.96
0.03
4.9
3.9
1.43
1.48
mmol/l
0.68
109
1109
119
1193
0.99
0.00
4.7
4.0
4.74
4.67
mmol/l
0.28
110
1121
54
545
0.99
0.00
2.5
2.6
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
8
0.00
-0.00
0.0
2.3
—
—
—
0
0
0
9
0.00
-0.00
0.0
2.1
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
3.9
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
8
0.00
-0.00
0.0
2.3
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
10.08
—
0
5
0
7
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
216.20
—
0
5
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
2.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
3.9
—
—
—
0
0
0
8
0.00
-0.00
0.0
2.3
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint G6_AUTOTHUNS and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_AUTOTHUNS | 2.676 [1.8, 3.98] | < 0.001 |
| Birth year | 0.995 [0.99, 1.0] | 0.258 |
During the follow-up period (1.1.1998 — 31.12.2019), 87 out of 362 females with G6_AUTOTHUNS died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_AUTOTHUNS | 2.681 [2.0, 3.6] | < 0.001 |
| Birth year | 0.986 [0.98, 1.0] | 0.004 |
During the follow-up period (1.1.1998 — 31.12.2019), 159 out of 402 males with G6_AUTOTHUNS died.
Mortality risk
Mortality risk for people of age
years, who have G6_AUTOTHUNS.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.252% | 0.419% |
| 5 | 1.563% | 3.014% |
| 10 | 3.867% | 7.291% |
| 15 | 7.165% | 13.851% |
| 20 | 12.414% | 22.741% |
Relationships between endpoints
↥Index endpoint: G6_AUTOTHUNS – Other and unspecified disorders of autonomic nervous system
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data